RxDoctor Payments Data

Ester Hare, MD

Internal Medicine · Orangeburg, SCNPI 1538144795

Payments from drug & device makers

$1,318in general payments, 2019–2025

Across 63 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$426
  • Boehringer Ingelheim$197
  • Novo Nordisk$128
  • Lilly USA, LLC$125
  • Pfizer$96
  • Sanofi$71
  • plus $275 from 12 others

What the payments were for

  • Food & beverage$1,318100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,318 in reported general payments places this provider in the 70th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$163,414
Medicare patients
219
Services billed
2,790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide203$263,007
JardianceEmpagliflozin205$183,201
EliquisApixaban96$78,469
TrulicityDulaglutide43$61,647
OzempicSemaglutide36$42,579
FarxigaDapagliflozin Propanediol54$41,687
LinzessLinaclotide37$40,330
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog49$36,639
Janumet XrSitagliptin Phos/Metformin Hcl31$30,026
JanuviaSitagliptin Phosphate27$24,685
JanumetSitagliptin Phos/Metformin Hcl20$23,462
XareltoRivaroxaban16$20,131
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$16,597
Tresiba Flextouch U-100Insulin Degludec33$15,776
KerendiaFinerenone16$14,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$125$324,653246 claims
Boehringer IngelheimJardiance$197$183,201205 claims
PfizerEliquis$96$78,46996 claims
MerckJanumet Xr, Januvia, Janumet$38$78,17378 claims
AstraZenecaFarxiga, Symbicort$17$46,20570 claims
Novo NordiskOzempic$128$42,57936 claims
Johnson & JohnsonXarelto$18$20,13116 claims
BayerKerendia$426$14,14716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Orangeburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →